Lung cancer resistance mystery: new study digs into entrectinib failures
NCT ID NCT07199959
First seen Oct 01, 2025 · Last updated Jun 20, 2026 · Updated 40 times
Summary
This observational study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tissue or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By using genetic sequencing, they hope to identify the mechanisms behind acquired resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Entrectinib
What this could lead to
If successful, this could help doctors understand why some lung cancers stop responding to entrectinib, potentially leading to better treatment strategies.
What could go wrong
This is a small, observational study that only looks back at past cases. It won't test new treatments, and findings may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.